Josh Cohen
About Josh Cohen
Josh Cohen Co-CEO & Co-Founder
Josh Cohen is the Co-CEO and Co-Founder of Amylyx Pharmaceuticals. His leadership role at the company involves overseeing key strategic and operational decisions. Amylyx Pharmaceuticals is focused on developing treatments for neurodegenerative diseases.
Josh Cohen Neurodegenerative Disease Research
Josh Cohen's interest in neurodegenerative diseases began during his studies at Brown University. He was driven by a fundamental question: 'Why do neurons die?' This curiosity led him to explore various aspects of neurodegenerative disease mechanisms, laying the groundwork for his future endeavors.
Josh Cohen Brown University Education
Josh Cohen studied neurodegenerative diseases at Brown University. His academic focus provided him with a deep understanding of the biological and chemical processes involved in neurodegeneration. This education was pivotal in forming the basis for his later research and professional pursuits.
Founding of Amylyx Pharmaceuticals
Josh Cohen co-founded Amylyx Pharmaceuticals with a classmate from Brown University. Their collaborative effort was the culmination of years of data accumulation and research. The company's mission is to develop novel treatments for neurodegenerative diseases, leveraging the extensive research conducted by Cohen and his co-founder.